List Of Non Gamstop Casinos UKCasinos Not On GamstopNon Gamstop CasinosCasino Non Aams ItaliaNon Gamstop Casinos
Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

hypertension - strategy - non diabetic patients  

hypertension - strategy - all type of patients  


Related trials

Cardio-Sis, 2009 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ACCORD blood pressure, 2008 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

REIN-2, 2005 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

AASK, 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

Toto, 1995 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

HOT, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

MDRD, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie



See also:

  • All hypertension clinical trials
  • All clinical trials of strategy
  • All clinical trials of more intensive blood pressure lowering strategie
    		•  

    REIN-2 study, 2005

    Treatments

    Studied treatment intensified (systolic/diastolic
    Control treatment conventional (diastolic
    Treatments description
    Achieved systolic blood 129.6/133.7 
    Achieved diastolic blood pressure 79.5/82.3 

    Patients

    Patients patients with non-diabetic proteinuric nephropathies receiving background treatment with the ACE inhibitor ramipril

    Method and design

    Randomized effectives 169 / 169 (studied vs. control)
    Blinding open
    Follow-up duration 36 months
    Primary endpoint end-stage renal disease


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Cardiovascular death

    1 / 169
         2 / 169
         classic 0,50 [0,05;5,46]

    Serious adverse event

    39 / 169
         28 / 169
         classic 1,39 [0,90;2,15]

    All cause death

    2 / 169
         3 / 169
         classic 0,67 [0,11;3,94]

    non cardiovascular death

    1 / 169
         1 / 169
         classic 1,00 [0,06;15,86]

    End stage renal disease

    38 / 169
         34 / 169
         1,12 [0,74;1,69]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Cardiovascular death 1 / 169 (0,6%) 2 / 169 (1,2%) 0,50 [0,05;5,46]   11040 
    All cause death 2 / 169 (1,2%) 3 / 169 (1,8%) 0,67 [0,11;3,94]   11040 
    non cardiovascular death 1 / 169 (0,6%) 1 / 169 (0,6%) 1,00 [0,06;15,86]   11040 
    Serious adverse event 39 / 169 (23,1%) 28 / 169 (16,6%) 1,39 [0,90;2,15]   11040 
    End stage renal disease 38 / 169 (22,5%) 34 / 169 (20,1%) 1,12 [0,74;1,69]   11040 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11040: Arguedas JA, Perez MI, Wright JMTreatment blood pressure targets for hypertension.Cochrane Database Syst Rev 2009;:CD004349

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Cardiovascular death 5,92‰ 1,18% -5,9‰
    All cause death 1,18% 1,78% -5,9‰
    non cardiovascular death 5,92‰ 5,92‰ 0,0‰
    Serious adverse event 23,08% 16,57% 6,5%
    End stage renal disease 22,49% 20,12% 2,4%


    Reference(s)

    Trials register # NA
    • Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.. Lancet 2005;365:939-46
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend

    Digital discoveries